Search

Your search keyword '"Kazumasa Mogi"' showing total 2 results
Start Over Author "Kazumasa Mogi" Journal current oncology
2 results on '"Kazumasa Mogi"'

1. Significance of Concurrent Chemoradiotherapy as Primary Treatment in Patients with Metastatic Cervical Cancer

Author

Satomi Hattori, Nobuhisa Yoshikawa, Kazumasa Mogi, Kosuke Yoshida, Masato Yoshihara, Satoshi Tamauchi, Yoshiki Ikeda, Akira Yokoi, Kimihiro Nishino, Kaoru Niimi, Shiro Suzuki, and Hiroaki Kajiyama

Subjects
metastatic cervical cancer, tumor size, concurrent chemoradiotherapy, biomarker, prognosis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

(1) This study investigated the prognostic impact of tumor size in patients with metastatic cervical cancer. (2) Methods: Seventy-three cervical cancer patients in our institute were stratified into two groups based on distant metastasis: para-aortic lymph node metastasis alone (IIIC2) or spread to distant visceral organs with or without para-aortic lymph node metastasis (IVB) to identify primary tumor size and concurrent chemoradiotherapy. (3) Results: The overall survival (OS) for patients with a tumor >6.9 cm in size was significantly poorer than that for patients with a tumor ≤6.9 cm in the IVB group (p = 0.0028); the corresponding five-year OS rates in patients with a tumor ≤6.9 and >6.9 cm were 53.3% and 13.4%, respectively. In the multivariate analysis, tumor size and primary treatment were significantly associated with survival in metastatic cervical cancer. (4) Conclusions: Tumor size ≤6.9 cm and concurrent chemoradiotherapy as the primary treatment were favorable prognostic factors for patients with metastatic cervical cancer.

Published
2021
Full Text
View/download PDF

2. Significance of Concurrent Chemoradiotherapy as Primary Treatment in Patients with Metastatic Cervical Cancer

Author

Hiroaki Kajiyama, Kazumasa Mogi, Akira Yokoi, Satoshi Tamauchi, Kaoru Niimi, Masato Yoshihara, Kimihiro Nishino, Yoshiki Ikeda, Shiro Suzuki, Satomi Hattori, Nobuhisa Yoshikawa, and Kosuke Yoshida

Subjects
Oncology, medicine.medical_specialty, Uterine Cervical Neoplasms, Primary tumor size, metastatic cervical cancer, Article, concurrent chemoradiotherapy, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, In patient, RC254-282, Metastatic cervical cancer, Cervical cancer, 030219 obstetrics & reproductive medicine, Tumor size, business.industry, tumor size, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Chemoradiotherapy, medicine.disease, Concurrent chemoradiotherapy, 030220 oncology & carcinogenesis, Carcinoma, Squamous Cell, biomarker, Biomarker (medicine), Female, Primary treatment, prognosis, Lymph Nodes, business
Abstract

(1) This study investigated the prognostic impact of tumor size in patients with metastatic cervical cancer. (2) Methods: Seventy-three cervical cancer patients in our institute were stratified into two groups based on distant metastasis: para-aortic lymph node metastasis alone (IIIC2) or spread to distant visceral organs with or without para-aortic lymph node metastasis (IVB) to identify primary tumor size and concurrent chemoradiotherapy. (3) Results: The overall survival (OS) for patients with a tumor &gt, 6.9 cm in size was significantly poorer than that for patients with a tumor ≤6.9 cm in the IVB group (p = 0.0028), the corresponding five-year OS rates in patients with a tumor ≤6.9 and &gt, 6.9 cm were 53.3% and 13.4%, respectively. In the multivariate analysis, tumor size and primary treatment were significantly associated with survival in metastatic cervical cancer. (4) Conclusions: Tumor size ≤6.9 cm and concurrent chemoradiotherapy as the primary treatment were favorable prognostic factors for patients with metastatic cervical cancer.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results